Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico

Early Post-Marketing Study of Eliquis (Apixaban), in Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE in Adults

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02345343

Enrollment

100

Registered

2015-01-26

Start date

2015-05-04

Completion date

2015-10-07

Last updated

2017-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Vein Thrombosis, Pulmonary Embolism

Brief summary

The primary objective of the study is to report adverse events of on-treatment AEs by the treating physicians during a specified 24-month study period in patients with venous thromboembolism at the sentinel site(s) for the National Center of Pharmacovigilance (CNFV) in Mexico.

Interventions

DRUGApixaban

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Patients 18 years old with DVT and PE at the sentinel site who received at least 1 dose of apixaban for the treatment and/or prevention of recurrence of DVT and PE during the specified 24-month study period

Exclusion criteria

* Subjects who received apixaban as part of a clinical trial * Subjects who received apixaban for any indication other than local approved * Contraindications included in the approved Mexican prescribing information

Design outcomes

Primary

Measure	Time frame
The number of adverse events (AEs) notified to health authorities (HAs) of on-treatment AEs by the treating physicians	Up to 24-month study period

Secondary

Measure	Time frame
The AEs reported to HA in a table format identifying the report number, patient ID number, and type of AE	Up to 24-month study period

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026